Novartis Q1 2026: Growth Brands and Pipeline Advance Despite Generic Headwinds

Novartis ( (NVS) ) has shared an announcement.

On April 28, 2026, Novartis reported first-quarter 2026 results showing net sales slipping 5% at constant currencies to USD 13.1 billion, as strong volume growth and surging priority brands were more than offset by U.S. generic erosion and pricing pressure. Core operating income fell 14% at constant currencies and net income declined 13%, although free cash flow held broadly steady at USD 3.3 billion, and the company reaffirmed full-year 2026 guidance for low single-digit net sales growth and a low single-digit decline in core operating income.

The quarter underscored the strength of Novartis’s growth drivers, with Kisqali, Pluvicto, Kesimpta, Scemblix, Leqvio and Fabhalta all posting double‑digit to triple‑digit constant‑currency gains, partially counterbalancing declines in older products such as the Zolgensma group. Novartis advanced its R&D pipeline with positive late-stage data for remibrutinib and Fabhalta, new regulatory milestones for Cosentyx and ianalumab, and completed the acquisition of Avidity to add three late-stage neuromuscular medicines, steps that support its long‑term growth ambitions despite near‑term margin pressure from higher R&D spending and generic competition.

The most recent analyst rating on (NVS) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.

Spark’s Take on NVS Stock

According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.

Score is driven primarily by strong underlying financial quality (high margins and strong free cash flow) and a bullish technical trend. The key constraints are management’s softer 2026 profit outlook amid significant LOE/generic headwinds and a valuation that looks reasonable rather than clearly discounted.

To see Spark’s full report on NVS stock, click here.

More about Novartis

Novartis is a pure-play innovative medicines company headquartered in Basel, Switzerland, focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. It prioritizes established technology platforms in chemistry and biotherapeutics, alongside emerging platforms such as gene and cell therapy, radioligand therapy and xRNA, with a commercial focus on the U.S., China, Germany and Japan.

Average Trading Volume: 2,243,961

Technical Sentiment Signal: Buy

Current Market Cap: $263.9B

For detailed information about NVS stock, go to TipRanks’ Stock Analysis page.